Chamber and committees

The Scottish Government has no plans to review the arrangements currently in place through which qualified clinicians, taking on board the patients’ medical history and lifestyle, agree with their patients, on a case-by-case basis, whether they would benefit from opioid substitution treatment (OST) or not. It is for patients and their clinicians to determine what is best for them and this will include agreement on the type and dosage of relevant OST. Methadone remains the most popularly used type of OST in Scotland, and there is strong evidence that supports its use.

From the recently published National Records Scotland (NRS) report on drug related deaths in 2020, methadone, on its own, was implicated in a very small number of deaths (7). However, it is increasingly implicated in deaths alongside other drugs suggesting that poly-drug use and non-compliance with treatment is the biggest factor. To increase our understanding in this area, and to inform policy making going forward, the Scottish Government is commissioning research to investigate the role and risks of methadone in drug related deaths.

Ministers are also keen to make sure as wide a range of OST and other treatment options are available, particularly long-acting buprenorphine – which has been deployed successfully in Scottish prisons throughout the pandemic. In addition, publication of the new Medication Assisted Treatment (MAT) standards on 31 May 2021, emphasises the importance of allowing people to make informed choices about the type of medication and help available to them and to be supported to make an informed choice with regards to what medication to use for MAT.